^
Association details:
| Biomarker: | EGFR T790M + EGFR C797S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
Published date:
04/28/2021
Excerpt:
...52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma...The patient subsequently received a regimen of osimertinib and anlotinib combined with chemotherapy, followed by osimertinib and anlotinib maintenance treatment, and achieved a PR lasting for 9 months....first clinical evidence that the osimertinib and anlotinib-based regimen may be an effective therapy in overcoming resistance mediated by T790M-cis-C797S.
DOI:
https://doi.org/10.2147/OTT.S298655
